CY1118091T1 - Ανοσολογικως χρησιμα αλατα αργινινης - Google Patents
Ανοσολογικως χρησιμα αλατα αργινινηςInfo
- Publication number
- CY1118091T1 CY1118091T1 CY20161101006T CY161101006T CY1118091T1 CY 1118091 T1 CY1118091 T1 CY 1118091T1 CY 20161101006 T CY20161101006 T CY 20161101006T CY 161101006 T CY161101006 T CY 161101006T CY 1118091 T1 CY1118091 T1 CY 1118091T1
- Authority
- CY
- Cyprus
- Prior art keywords
- immunology
- useful
- arginine salts
- arginine
- salts
- Prior art date
Links
- 125000000637 arginyl group Chemical class N[C@@H](CCCNC(N)=N)C(=O)* 0.000 title 1
- 239000002671 adjuvant Substances 0.000 abstract 1
- 238000001727 in vivo Methods 0.000 abstract 1
- 150000003839 salts Chemical group 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
- C07F9/6561—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing systems of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring or ring system, with or without other non-condensed hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Immunology (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261608011P | 2012-03-07 | 2012-03-07 | |
| PCT/EP2013/054548 WO2013131985A1 (en) | 2012-03-07 | 2013-03-07 | Immunologically useful arginine salts |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CY1118091T1 true CY1118091T1 (el) | 2017-06-28 |
Family
ID=47843276
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CY20161101006T CY1118091T1 (el) | 2012-03-07 | 2016-10-10 | Ανοσολογικως χρησιμα αλατα αργινινης |
Country Status (18)
| Country | Link |
|---|---|
| US (1) | US9320748B2 (enExample) |
| EP (1) | EP2822947B1 (enExample) |
| JP (1) | JP6325986B2 (enExample) |
| CN (1) | CN104203946B (enExample) |
| AU (1) | AU2013229466A1 (enExample) |
| CA (1) | CA2865759C (enExample) |
| CY (1) | CY1118091T1 (enExample) |
| DK (1) | DK2822947T3 (enExample) |
| ES (1) | ES2597755T3 (enExample) |
| HR (1) | HRP20161354T1 (enExample) |
| HU (1) | HUE030175T2 (enExample) |
| LT (1) | LT2822947T (enExample) |
| MX (1) | MX346678B (enExample) |
| PL (1) | PL2822947T3 (enExample) |
| PT (1) | PT2822947T (enExample) |
| RU (1) | RU2014140336A (enExample) |
| SI (1) | SI2822947T1 (enExample) |
| WO (1) | WO2013131985A1 (enExample) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9950062B2 (en) | 2009-09-02 | 2018-04-24 | Glaxosmithkline Biologicals Sa | Compounds and compositions as TLR activity modulators |
| JP2013538217A (ja) | 2010-09-01 | 2013-10-10 | ノバルティス アーゲー | 不溶性金属塩への免疫増強物質の吸着 |
| CN103533954B (zh) | 2011-03-02 | 2015-09-09 | 诺华股份有限公司 | 含较低剂量的抗原和/或佐剂的联合疫苗 |
| CA2866406A1 (en) | 2012-03-08 | 2013-09-12 | Novartis Ag | Adjuvanted formulations of booster vaccines |
| MX377794B (es) | 2014-03-26 | 2025-03-10 | Glaxosmithkline Biologicals Sa | Antigenos estafilococicos mutantes. |
| EP3061826A1 (en) | 2015-02-27 | 2016-08-31 | Novartis AG | Flavivirus replicons |
| WO2021178306A1 (en) * | 2020-03-01 | 2021-09-10 | Dynavax Technologies Corporation | Coronavirus vaccines comprising a tlr9 agonist |
| WO2022192097A1 (en) * | 2021-03-06 | 2022-09-15 | Mind Medicine, Inc. | Formulations of psilocin that have enhanced stability |
| GB202215414D0 (en) | 2022-10-18 | 2022-11-30 | Glaxosmithkline Biologicals Sa | Vaccine |
Family Cites Families (29)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6699474B1 (en) | 1990-08-20 | 2004-03-02 | Erich Hugo Cerny | Vaccine and immunserum against drugs of abuse |
| AU3630093A (en) | 1992-03-02 | 1993-10-05 | Biocine S.P.A. | Helicobacter pylori proteins useful for vaccines and diagnostics |
| FR2718452B1 (fr) | 1994-04-06 | 1996-06-28 | Pf Medicament | Elément d'immunogène, agent immunogène, composition pharmaceutique et procédé de préparation. |
| JPH10502365A (ja) | 1994-07-01 | 1998-03-03 | リカン・リミテッド | ヘリコバクタータンパク質およびワクチン |
| EP0909323B1 (en) | 1996-01-04 | 2007-02-28 | Novartis Vaccines and Diagnostics, Inc. | Helicobacter pylori bacterioferritin |
| GB9828000D0 (en) | 1998-12-18 | 1999-02-10 | Chiron Spa | Antigens |
| ATE440861T1 (de) | 2000-07-03 | 2009-09-15 | Novartis Vaccines & Diagnostic | Immunisierung gegen chlamydia pneumoniae |
| FR2827605B1 (fr) | 2001-07-20 | 2004-07-16 | Pf Medicament | Nouveaux peptides derives de la proteine g du vrs et leur utilisation dans un vaccin |
| ES2386386T3 (es) | 2001-12-12 | 2012-08-20 | Novartis Vaccines And Diagnostics S.R.L. | Inmunización contra Chlamydia trachomatis |
| GB0211118D0 (en) | 2002-05-15 | 2002-06-26 | Polonelli Luciano | Vaccines |
| EP2351579B1 (en) | 2002-10-11 | 2016-09-21 | Novartis Vaccines and Diagnostics S.r.l. | Polypeptide vaccines for broad protection against hypervirulent meningococcal lineages |
| WO2005002619A2 (en) | 2003-06-26 | 2005-01-13 | Chiron Corporation | Immunogenic compositions for chlamydia trachomatis |
| WO2005084306A2 (en) | 2004-03-02 | 2005-09-15 | Chiron Corporation | Immunogenic compositions for chlamydia pneunomiae |
| AU2006214064B2 (en) | 2005-02-18 | 2012-04-26 | J. Craig Venter Institute, Inc. | Proteins and nucleic acids from meningitis/sepsis-associated escherichia coli |
| JP2008530245A (ja) | 2005-02-18 | 2008-08-07 | ノバルティス ヴァクシンズ アンド ダイアグノスティクス， インコーポレイテッド | 尿路病原性菌株由来の抗原 |
| AU2006259858A1 (en) | 2005-05-12 | 2006-12-28 | Novartis Vaccines And Diagnostics S.R.L. | Immunogenic compositions for Chlamydia trachomatis |
| GB0524066D0 (en) | 2005-11-25 | 2006-01-04 | Chiron Srl | 741 ii |
| WO2007110700A2 (en) | 2005-12-22 | 2007-10-04 | Novartis Vaccines And Diagnostics, Srl. | Chlamydial antigens |
| EP2586790A3 (en) | 2006-08-16 | 2013-08-14 | Novartis AG | Immunogens from uropathogenic Escherichia coli |
| HRP20120433T1 (en) | 2007-10-19 | 2012-07-31 | Novartis@Ag | Meningococcal vaccine formulations |
| EP2419129A2 (en) | 2009-04-14 | 2012-02-22 | Novartis AG | Compositions for immunising against staphylococcus aerus |
| ES2531115T3 (es) | 2009-06-01 | 2015-03-10 | Novartis Ag | Combinaciones de clados de RrgB neumocócicos |
| CA2765112A1 (en) * | 2009-06-10 | 2010-12-16 | Novartis Ag | Benzonaphthyridine-containing vaccines |
| WO2011024072A2 (en) | 2009-08-27 | 2011-03-03 | Novartis Ag | Hybrid polypeptides including meningococcal fhbp sequences |
| US9950062B2 (en) * | 2009-09-02 | 2018-04-24 | Glaxosmithkline Biologicals Sa | Compounds and compositions as TLR activity modulators |
| JO3257B1 (ar) | 2009-09-02 | 2018-09-16 | Novartis Ag | مركبات وتركيبات كمعدلات لفاعلية tlr |
| JP2013538217A (ja) | 2010-09-01 | 2013-10-10 | ノバルティス アーゲー | 不溶性金属塩への免疫増強物質の吸着 |
| US10286056B2 (en) | 2011-01-27 | 2019-05-14 | Glaxosmithkline Biologicals S.A. | Adjuvant nanoemulsions with crystallisation inhibitors |
| SG11201400210RA (en) * | 2011-09-01 | 2014-03-28 | Novartis Ag | Adjuvanted formulations of staphylococcus aureus antigens |
-
2013
- 2013-03-07 RU RU2014140336A patent/RU2014140336A/ru not_active Application Discontinuation
- 2013-03-07 LT LTEP13708142.8T patent/LT2822947T/lt unknown
- 2013-03-07 US US14/381,513 patent/US9320748B2/en active Active
- 2013-03-07 HU HUE13708142A patent/HUE030175T2/en unknown
- 2013-03-07 AU AU2013229466A patent/AU2013229466A1/en not_active Abandoned
- 2013-03-07 EP EP13708142.8A patent/EP2822947B1/en active Active
- 2013-03-07 HR HRP20161354TT patent/HRP20161354T1/hr unknown
- 2013-03-07 WO PCT/EP2013/054548 patent/WO2013131985A1/en not_active Ceased
- 2013-03-07 JP JP2014560367A patent/JP6325986B2/ja active Active
- 2013-03-07 PL PL13708142T patent/PL2822947T3/pl unknown
- 2013-03-07 CA CA2865759A patent/CA2865759C/en active Active
- 2013-03-07 SI SI201330288A patent/SI2822947T1/sl unknown
- 2013-03-07 PT PT137081428T patent/PT2822947T/pt unknown
- 2013-03-07 DK DK13708142.8T patent/DK2822947T3/en active
- 2013-03-07 ES ES13708142.8T patent/ES2597755T3/es active Active
- 2013-03-07 MX MX2014010423A patent/MX346678B/es active IP Right Grant
- 2013-03-07 CN CN201380012851.1A patent/CN104203946B/zh active Active
-
2016
- 2016-10-10 CY CY20161101006T patent/CY1118091T1/el unknown
Also Published As
| Publication number | Publication date |
|---|---|
| EP2822947B1 (en) | 2016-08-03 |
| JP6325986B2 (ja) | 2018-05-16 |
| CA2865759A1 (en) | 2013-09-12 |
| PT2822947T (pt) | 2016-09-26 |
| LT2822947T (lt) | 2016-10-10 |
| DK2822947T3 (en) | 2016-09-19 |
| MX346678B (es) | 2017-03-29 |
| HRP20161354T1 (hr) | 2016-12-02 |
| JP2015511957A (ja) | 2015-04-23 |
| CA2865759C (en) | 2020-07-21 |
| HUE030175T2 (en) | 2017-04-28 |
| AU2013229466A1 (en) | 2014-09-04 |
| EP2822947A1 (en) | 2015-01-14 |
| US9320748B2 (en) | 2016-04-26 |
| SI2822947T1 (sl) | 2016-10-28 |
| US20150125475A1 (en) | 2015-05-07 |
| RU2014140336A (ru) | 2016-04-27 |
| CN104203946B (zh) | 2017-03-22 |
| CN104203946A (zh) | 2014-12-10 |
| PL2822947T3 (pl) | 2017-01-31 |
| WO2013131985A1 (en) | 2013-09-12 |
| MX2014010423A (es) | 2014-09-22 |
| ES2597755T3 (es) | 2017-01-20 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CY1123958T1 (el) | Μεθοδος παρασκευης παραγωγων και ενδιαμεσων καρβαμοϋλπυριδονης | |
| CY1122222T1 (el) | Συνθεση βορονικων αλατων και χρησεις αυτων | |
| UY34782A (es) | Anticuerpos humanos para fel d1 y métodos para usarlos. | |
| BR112013023241A2 (pt) | melhorias para entidades biológicas imobilizadas | |
| UA116920C2 (uk) | Інгібітори fgfr4 | |
| CR20150507A (es) | Inhibidores de histona desmetilasas | |
| BR112015021521A2 (pt) | anticorpos anti-crth2 e métodos para seu uso | |
| EA201491357A1 (ru) | Анти-lrp5 антитела и способы их применения | |
| EP2713867A4 (en) | MAGNETIC ZEPHALOGRAPHY SOURCE IMAGING | |
| CO7151511A2 (es) | Derivado de cicloalcano | |
| BR112013029785A2 (pt) | dispositivo de varredura para interferometria de coerência baixa | |
| EA201390929A1 (ru) | Антитела к pcsk9 и способы их применения | |
| UY34406A (es) | Compuestos y métodos para mejorar la respuesta inmune innata | |
| HRP20170840T1 (hr) | Supstituirani ksantini i metode njihove uporabe | |
| TR201908418T4 (tr) | Sürdürülebilir immünoterapi için yöntem ve kompozisyonlar. | |
| BR112015012907A2 (pt) | composição de cuidado pessoal | |
| TWD158887S (zh) | 粉餅盒 | |
| MX346678B (es) | Sales de arginina utiles inmunologicamente. | |
| EA201201667A1 (ru) | Способ получения l-аргининовой соли периндоприла | |
| JOP20140215B1 (ar) | موصل لتسهيل رفع الأجزاء البالية | |
| BR112014000256A2 (pt) | formulação de microemulsões transparentes e nutritivas | |
| CO7350653A2 (es) | Retinoides y uso de los mismos | |
| FR3005367B1 (fr) | Detecteur compact de presence humaine | |
| MX2014015039A (es) | Inhibidores de fbx03. | |
| DK3011972T3 (da) | Medicinsk sammensætning til fremme af syntese af protoporphyrin IX |